InvestorsHub Logo
Followers 484
Posts 60914
Boards Moderated 18
Alias Born 09/20/2001

Re: Boogins post# 4387

Sunday, 04/30/2017 7:58:26 AM

Sunday, April 30, 2017 7:58:26 AM

Post# of 21536
Not without safety data in an elderly population.. absolutely not.

No approval, and no partnership at this stage.

Nine people with one treatment is not a proper 2a, and adverse safety reactions is likely to be the reason they only went for one round of therapy and shortened the 2b to three months.

Don't forget those 148 people included the control arm too...


Agreed, it is a very low probability that after a small 2a study that Bryostatin would be green lighted, but the possibility is there because the situation is so unusual: AD has literally no effective therapy for it and there are millions with the disease. If there were ever a situation where a drug could be approved via a small study it is this.





In Peace, In War

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News